Immune-Mediated Mechanisms Potentially Regulate the Disease Time-Course of Duchenne Muscular Dystrophy and Provide Targets for Therapeutic Intervention

PM and R

Volumn 1, Issue 8, 2009, Pages 755-768

  Evans, Nicholas P ^a   Misyak, Sarah A ^b   Robertson, John L ^a   Bassaganya Riera, Josep ^b   Grange, Robert W ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BINDARIT; CD4 ANTIGEN; CD8 ANTIGEN; CURCUMIN; DYSTROPHIN; EPIGALLOCATECHIN GALLATE; ETANERCEPT; GAMMA INTERFERON; GLYCOPROTEIN; I KAPPA B KINASE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PROTEIN BCL 3; PYRROLIDINE DITHIOCARBAMATE; RANTES; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CYTOSKELETON; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EOSINOPHIL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOREGULATION; INFLAMMATION; LETHALITY; MACROPHAGE; MAST CELL; MEMBRANE DAMAGE; MUSCLE CONTRACTION; MUSCLE FIBER MEMBRANE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AGE FACTORS; ANIMALS; CYTOKINES; HUMANS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; NF-KAPPA B;

EID: 68949143544     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2009.04.010     Document Type: Review

References (111)

1. Blake D.J., Weir A., Newey S.E., and Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82 (2002) 291-329
2. Tidball J.G., and Wehling-Henricks M. Evolving therapeutic strategies for Duchenne muscular dystrophy: Targeting downstream events. Pediatr Res 56 (2004) 831-841
3. Straub V., and Campbell K.P. Muscular dystrophies and the dystrophin-glycoprotein complex. Curr Opin Neurol 10 (1997) 168-175
4. Durbeej M., and Campbell K.P. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 12 (2002) 349-361
5. Oak S.A., Zhou Y.W., and Jarrett H.W. Skeletal muscle signaling pathway through the dystrophin glycoprotein complex and Rac1. J Biol Chem 278 (2003) 39287-39295
6. Spence H.J., Yun-Ju C., and Steven J.W. Muscular dystrophies, the cytoskeleton and cell adhesion. Bioessays 24 (2002) 542-552
7. Pasternak C., Wong S., and Elson E.L. Mechanical function of dystrophin in muscle cells. J Cell Biol 128 (1995) 355-361
8. Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., and Sweeney H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90 (1993) 3710-3714
9. Kumar A., and Boriek A.M. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: A possible role in Duchenne muscular dystrophy. FASEB J 17 (2003) 386-396
10. Kumar A., Khandelwal N., Malya R., Reid M.B., and Boriek A.M. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J 18 (2004) 102-113
11. Porter J.D., Guo W., Merriam A.P., et al. Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord 13 (2003) 223-235
12. Carnwath J.W., and Shotton D.M. Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. J Neurosci 80 (1987) 39-54
13. Spencer M.J., Montecino-Rodriguez E., Dorshkind K., and Tidball J.G. Helper (CD4+) and cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol 98 (2001) 235-243
14. Wehling M., Spencer M.J., and Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 155 (2001) 123-132
15. Chen Y.W., Nagaraju K., Bakay M., et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65 (2005) 826-834
16. Pescatori M., Broccolini A., Minetti C., et al. Gene expression profiling in the early phases of DMD: A constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 21 (2007) 1210-1226
17. Porter J.D., Khanna S., Kaminski H.J., et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 11 (2002) 263-272
18. Porter J.D., Merriam A.P., Leahy P., Gong B., and Khanna S. Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum Mol Genet 12 (2003) 1813-1821
19. Arahata K., and Engel A. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 16 (1984) 193-208
20. Engel A., and Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 17 (1986) 704-721
21. Engel A.G., and Franzinin-Armstrong C. Dystrophinopathies. In: Engel A.G., and Ozawa E. (Eds). Myology. 3rd ed. (2004), McGraw-Hill, New York, NY 961-1026
22. Gussoni E., Pavlath G.K., Miller R.G., et al. Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol 153 (1994) 4798-4805
23. Mantegazza R., Andreetta F., Bernasconi P., et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. J Clin Invest 91 (1993) 2880-2886
24. Villalta S.A., Nguyen H.X., Deng B., Gotoh T., and Tidball J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 18 (2009) 482-496
25. Hodgetts S., Radley H., Davies M., and Grounds M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord 16 (2006) 591-602
26. St-Pierre S.J., Chakkalakal J.V., Kolodziejczyk S.M., Knudson J.C., Jasmin B.J., and Megeney L.A. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J 18 (2004) 1937-1939
27. De Luca A., Nico B., Liantonio A., et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol 166 (2005) 477-489
28. Radley H.G., and Grounds M.D. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol Dis 23 (2006) 387-397
29. Grounds M.D., and Torrisi J.O. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18 (2004) 676-682
30. Tidball J.G. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 288 (2005) R345-R353
31. Tidball J.G., and Wehling-Henricks M. Damage and inflammation in muscular dystrophy: Potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol 17 (2005) 707-713
32. McDouall R., Dunn M., and Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 99 (1990) 199-217
33. Spencer M.J., and Tidball J.G. Do immune cells promote the pathology of dystrophin-deficient myopathies?. Neuromuscul Disord 11 (2001) 556-564
34. Cai B., Spencer M.J., Nakamura G., Tseng-Ong L., and Tidball J.G. Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors. Am J Pathol 156 (2000) 1789-1796
35. Gorospe J., Tharp M., Demitsu T., and Hoffman E. Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. Neuromuscul Disord 4 (1994) 325-333
36. Gorospe J., Tharp M., Hinckley J., Kornegay J., and Hoffman E. A role for mast cells in the progression of Duchenne muscular dystrophy?. Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 122 (1994) 44-56
37. Gorospe J.R.M., Nishikawa B.K., and Hoffman E.P. Recruitment of mast cells to muscle after mild damage. J Neurol Sci 135 (1996) 10-17
38. McDouall R., Dunn M., and Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci 89 (1989) 213-226
39. Karpati G., Pouliot Y., and Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 23 (1988) 64-72
40. Emslie-Smith A., Arahata K., and Engel A. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 20 (1989) 224-231
41. Appleyard S., Dunn M., Dubowitz V., and Rose M. Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet 1 (1985) 361-363
42. Spencer M.J., Walsh C.M., Dorshkind K.A., Rodriguez E.M., and Tidball J.G. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J Clin Invest 99 (1997) 2745-2751
43. Abu-Ghazaleh R.I., Gleich G.J., and Prendergast F.G. Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: a mechanism for toxicity. J Membr Biol 128 (1992) 153-164
44. Kroegel C., Costabel U., and Matthys H. Mechanism of membrane damage mediated by eosinophil major basic protein. Lancet 1 (1987) 1380-1381
45. Gilbert R.K., and Hawk W.A. The incidence of necrosis of muscle fibers in Duchenne type muscular dystrophy. Am J Pathol 43 (1963) 107-122
46. Lundberg I., Brengman J.M., and Engel A.G. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 63 (1995) 9-16
47. Acharyya S., Villalta S., Bakkar N., et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 117 (2007) 889-901
48. Rando T.A. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24 (2001) 1575-1594
49. Whitehead N.P., Yeung E.W., and Allen D.G. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 33 (2006) 657-662
50. Vandebrouck A., Sabourin J., Rivet J., et al. Regulation of capacitative calcium entries by alpha1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of alpha1-syntrophin. FASEB J 21 (2007) 608-617
51. Dogra C., Changotra H., Wergedal J.E., and Kumar A. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J Cell Physiol 208 (2006) 575-585
52. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
53. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-kappaB activity. Annu Rev Immunol 18 (2000) 621-663
54. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 3 (2002) 221-227
55. Sasaki C.Y., Barberi T.J., Ghosh P., and Longo D.L. Phosphorylation of RelA/p65 on serine 536 defines an IkappaBalpha-independent NF-kappaB pathway. J Biol Chem 280 (2005) 34538-34547
56. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.-Y., and Baldwin Jr. A.S. NF-kappaB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia. Science 289 (2000) 2363-2366
57. Zhou L., Porter J.D., Cheng G., et al. Temporal and spatial mRNA expression patterns of TGF-beta1, 2, 3 and TbetaRI, II, III in skeletal muscles of mdx mice. Neuromuscul Disord 16 (2006) 32-38
58. Gosselin L.E., Williams J.E., Deering M., Brazeau D., Koury S., and Martinez D.A. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30 (2004) 645-653
59. Andreetta F., Bernasconi P., Baggi F., et al. Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol 175 (2006) 77-86
60. Porreca E., Guglielmi M.D., Uncini A., et al. Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb Haemost 81 (1999) 543-546
61. Tews D.S., and Goebel H.H. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55 (1996) 342-347
62. Shireman P.K., Contreras-Shannon V., Ochoa O., Karia B.P., Michalek J.E., and McManus L.M. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. J Leukoc Biol 81 (2007) 775-785
63. Shireman P.K., Contreras-Shannon V., Reyes-Reyna S.M., Robinson S.C., and McManus L.M. MCP-1 parallels inflammatory and regenerative responses in ischemic muscle. J Surg Res 134 (2006) 145-157
64. Warren G.L., O'Farrell L., Summan M., et al. Role of CC chemokines in skeletal muscle functional restoration after injury. Am J Physiol Cell Physiol 286 (2004) C1031-C1036
65. Summan M., Warren G.L., Mercer R.R., et al. Macrophages and skeletal muscle regeneration: A clodronate-containing liposome depletion study. Am J Physiol Regul Integr Comp Physiol 290 (2006) R1488-R1495
66. Chazaud B., Sonnet C., Lafuste P., et al. Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth. J Cell Biol 163 (2003) 1133-1143
67. Dennis R.A., Trappe T.A., Simpson P., et al. Interleukin-1 polymorphisms are associated with the inflammatory response in human muscle to acute resistance exercise. J Physiol 560 (2004) 617-626
68. Grundtman C., Salomonsson S., Dorph C., Bruton J., Andersson U., and Lundberg I.E. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 56 (2007) 674-687
69. Lundberg I., Ulfgren A.K., Nyberg P., Andersson U., and Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40 (1997) 865-874
70. Cooney R.N., Maish III G.O., Gilpin T., Shumate M.L., Lang C.H., and Vary T.C. Mechanism of IL-1 induced inhibition of protein synthesis in skeletal muscle. Shock 11 (1999) 235-241
71. Broussard S.R., McCusker R.H., Novakofski J.E., et al. IL-1beta impairs insulin-like growth factor i-induced differentiation and downstream activation signals of the insulin-like growth factor i receptor in myoblasts. J Immunol 172 (2004) 7713-7720
72. Mourkioti F., and Rosenthal N. IGF-1, inflammation and stem cells: Interactions during muscle regeneration. Trends Immunol 26 (2005) 535-542
73. Li Y., and Reid M. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol 13 (2001) 483-487
74. Reid M., and Li Y. Tumor necrosis factor-alpha and muscle wasting: A cellular perspective. Respir Res 2 (2001) 269-272
75. Spencer M.J., Marino M.W., and Winckler W.M. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul Disord 10 (2000) 612-619
76. Van Erp C., Irwin N.G., and Hoey A.J. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 34 (2006) 327-334
77. Lagrota-Candido J., Canella I., Savino W., and Quirico-Santos T. Expression of extracellular matrix ligands and receptors in the muscular tissue and draining lymph nodes of mdx dystrophic mice. Clin Immunol 93 (1999) 143-151
78. Morrison J., Lu Q., Pastoret C., Partridge T., and Bou-Gharios G. T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab Invest 80 (2000) 881-891
79. Morrison J., Palmer D.B., Cobbold S., Partridge T., and Bou-Gharios G. Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse. Am J Pathol 166 (2005) 1701-1710
80. Farini A., Meregalli M., Belicchi M., et al. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. J Pathol 213 (2007) 229-238
81. Chakkalakal J.V., Stocksley M.A., Harrison M.A., et al. Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc Natl Acad Sci U S A 100 (2003) 7791-7796
82. Hussein M.R., Hamed S.A., Mostafa M.G., Abu-Dief E.E., Kamel N.F., and Kandil M.R. The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol 87 (2006) 451-461
83. Angelini C. The role of corticosteroids in muscular dystrophy: A critical appraisal. Muscle Nerve 36 (2007) 424-435
84. Balaban B., Matthews D.J., Clayton G.H., and Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil 84 (2005) 843-850
85. Connolly A.M., Schierbecker J., Renna R., and Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12 (2002) 917-925
86. Keeling R.M., Golumbek P.T., Streif E.M., and Connolly A.M. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 35 (2007) 43-48
87. Merlini L., Cicognani A., Malaspina E., et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 27 (2003) 222-227
88. Pradhan S., Ghosh D., Srivastava N.K., et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. J Neurol 253 (2006) 1309-1316
89. Barry F.P., and Murphy J.M. Mesenchymal stem cells: Clinical applications and biological characterization. Int J Biochem Cell Biol 36 (2004) 568-584
90. Le Blanc K., and Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 18 (2006) 586-591
91. Beyth S., Borovsky Z., Mevorach D., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105 (2005) 2214-2219
92. Chang C.J., Yen M.L., Chen Y.C., et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 24 (2006) 2466-2477
93. Maitra B., Szekely E., Gjini K., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 33 (2004) 597-604
94. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2 (2008) 141-150
95. Radley H.G., De Luca A., Lynch G.S., and Grounds M.D. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int J Biochem Cell Biol 39 (2007) 469-477
96. Kalliolias G.D., and Liossis S.N. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Invest Drugs 17 (2008) 349-359
97. Mirolo M., Fabbri M., Sironi M., et al. Impact of the anti-inflammatory agent bindarit on the chemokinome: Selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw 19 (2008) 119-122
98. Akhurst R.J. TGF-beta antagonists: Why suppress a tumor suppressor?. J Clin Invest 109 (2002) 1533-1536
99. Messina S., Bitto A., Aguennouz, et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Mh. Exp Neurol 198 (2006) 234-241
100. Feng W.Y. Metabolism of green tea catechins: An overview. Curr Drug Metab 7 (2006) 755-809
101. Chen P.C., Wheeler D.S., Malhotra V., Odoms K., Denenberg A.G., and Wong H.R. A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 26 (2002) 233-241
102. Yang F., Oz H.S., Barve S., de Villiers W.J., McClain C.J., and Varilek G.W. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 60 (2001) 528-533
103. Buetler T.M., Renard M., Offord E.A., Schneider H., and Ruegg U.T. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr 75 (2002) 749-753
104. Call J.A., Voelker K.A., Wolff A.V., et al. Endurance capacity in maturing mdx mice is markedly enhanced by combined voluntary wheel running and green tea extract. J Appl Physiol 105 (2008) 923-932
105. Dorchies O.M., Wagner S., Vuadens O., et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol 290 (2006) C616-C625
106. Nakae Y., Hirasaka K., Goto J., et al. Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: A quantitative histological, immunohistochemical and electrophysiological study. Histochem Cell Biol 129 (2008) 489-501
107. Pan Y., Chen C., Shen Y., et al. Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol Cells 25 (2008) 531-537
108. Durham W.J., Arbogast S., Gerken E., Li Y.P., and Reid M.B. Progressive nuclear factor-kappaB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 34 (2006) 298-303
109. Sen C.K., and Roy S. Relief from a heavy heart: Redox-sensitive NF-kappaB as a therapeutic target in managing cardiac hypertrophy. Am J Physiol Heart Circ Physiol 289 (2005) H17-H19
110. Siegel A.L., Bledsoe C., Lavin J., et al. Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse. Neuromuscul Disord 19 (2009) 131-139
111. Whitehead N.P., Pham C., Gervasio O.L., and Allen D.G. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol 586 (2008) 2003-2014